CryoPort Inc (OQ:CYRX)

Nov 27, 2023 07:30 am ET
Cryoport and NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership for Temperature-Controlled Supply Chain Services
Companies Will Partner to Provide Complete Supply Chain Solutions for the Life Science and Biopharmaceutical Industries
Nov 16, 2023 07:30 am ET
Cryoport's CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird Express
CRYOPDP's Acquisition of Bluebird Express Adds Further Domestic and International Transportation Services Strengthening CRYOPDP's U.S. Logistics Operations
Nov 08, 2023 03:05 pm ET
Cryoport Reports Third Quarter 2023 Financial Results
Third quarter 2023 commercial Cell and Gene Therapy revenue up 54% year-over-yearSupporting a record total of 670 clinical trials worldwide, with 81 in Phase 3Nine months 2023 revenue of $176 million Affirms full year 2023 revenue guidance of $233 - $243 millionNASHVILLE, Tenn., Nov. 8, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the life sciences, with a focus on the fast-growing cell and gene therapy industry, enabling the future of medicine for a new era of life sciences, today announced
Nov 02, 2023 08:30 am ET
Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH Acquisition
Strategic Acquisition Strengthens Condition Monitoring Systems and Logistics Management Capabilities for the Biopharmaceutical Industry Throughout Cryoport's Family of Companies
Oct 25, 2023 08:30 am ET
Cryoport to Report Third Quarter 2023 Financial Results on November 8, 2023
NASHVILLE, Tenn., Oct. 25, 2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, today announced that the Company will report financial results for the third quarter ended September 30, 2023 on Wednesday, November 8, 2023 after U.S. markets close.
Oct 12, 2023 08:30 am ET
Cryoport Inks New Multi-Year Supply Chain Solutions Agreement with Monash IVF
NASHVILLE, Tenn., Oct. 12, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, today announced that the Company has signed a new three-year supply chain solutions agreement with Monash IVF Group Limited (ASX: MVF), a leading provider of assisted reproductive services, as well as specialist women's imaging and diagnostic services in Australia and Southeast Asia.
Oct 10, 2023 08:30 am ET
Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies
Partnership Establishes Cryoport Systems' First U.K. Logistics Center to Support Future Expansion and Provide End-to-End Supply Chain Solutions for Advanced Therapy Manufacturers
Oct 09, 2023 04:05 pm ET
Be The Match BioTherapies® and Cryoport Partner to Accelerate the Development of Cell and Gene Therapies
Partnership will provide access to standardized and optimized apheresis collection, cryopreservation and bioprocessing processes throughout the U.S. and Europe
Sep 14, 2023 08:30 am ET
Cryoport Receives 2023 IMAPAC Asia Pacific Cell & Gene Therapy Excellence Award
Company Named "Best Cell & Gene Therapy Supplier – Cryogenic Storage"
Sep 12, 2023 11:00 am ET
The Law Offices of Frank R. Cruz Continues Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors
The Law Offices of Frank R. Cruz continues its investigation of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ:
Sep 11, 2023 12:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ:
Sep 11, 2023 09:30 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors
Law Offices of Howard G. Smith continues its investigation on behalf of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX) investors concerning the Company’s possible violations of federal securities laws.
Aug 25, 2023 05:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws.
Aug 02, 2023 05:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cryoport, Inc. - CYRX
Pomerantz LLP is investigating claims on behalf of investors of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Aug 02, 2023 08:30 am ET
Cryoport to Report Second Quarter 2023 Financial Results on August 9, 2023
NASHVILLE, Tenn., Aug. 2, 2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services for the fast growing cell and gene therapy industry, reproductive medicine and animal health industries, today announced that the Company will report financial results for the second quarter ended June 30, 2023 on Wednesday, August 9, 2023 after U.S. markets close.
Aug 01, 2023 04:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws.
Jul 29, 2023 07:00 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE: CYRX) for violations of the securities laws.
Jul 27, 2023 03:38 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cryoport, Inc. - CYRX
Pomerantz LLP is investigating claims on behalf of investors of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jul 25, 2023 06:01 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cryoport, Inc. - CYRX
NEW YORK, July 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or the "Company") (NASDAQ: CYRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 24, 2023 06:00 am ET
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws.
Jul 20, 2023 03:30 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws.
Jul 19, 2023 04:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cryoport, Inc. - CYRX
Pomerantz LLP is investigating claims on behalf of investors of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jul 19, 2023 06:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws.
Jul 18, 2023 08:24 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cryoport, Inc. - CYRX
NEW YORK, July 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or the "Company") (NASDAQ: CYRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 18, 2023 06:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws.
Jul 17, 2023 03:22 pm ET
Cryoport, Inc.: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises Cryoport, Inc. (“Cryoport,” or the “Company”) (NASDAQ: CYRX) investors that the firm has initiated an investigation into possible securities violations and may file a class action on behalf of investors....
Jul 17, 2023 02:48 pm ET
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. (“Cryoport” or “the Company”) (NYSE:
Jul 17, 2023 11:15 am ET
Investigation of Cryoport, Inc. (CYRX) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether Cryoport, Inc. (“Cryoport,” or the “Company”) (NASDAQ: CYRX) complied with federal securities laws.  On July 12, 2023, Cryoport announced preliminary financial results for the second quarter ended June...
Jul 14, 2023 12:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ:
Jul 14, 2023 09:30 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX) investors concerning the Company’s possible violations of federal securities laws.
Jul 14, 2023 06:00 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws.
Jul 13, 2023 02:14 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ:
Jul 12, 2023 04:05 pm ET
Cryoport Announces Certain Preliminary Results for Second Quarter & Updates 2023 Revenue Expectations
Second quarter results were impacted by weaker than expected global demand for capital equipment; clinical trial start delays; and slower than expected ramps from certain clientsSecond quarter revenue expected in the range of $56.5 - $57.5 millionFull year 2023 revenue now expected in the range of $233 - $243 millionLong-term outlook robust with cell and gene therapy industry expected to grow at a ten-year CAGR in excess of 22%NASHVILLE, Tenn., July 12, 2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and servi
Jun 29, 2023 08:39 am ET
IVFAustralia Selects Cryoport as Exclusive Supply Chain Solutions Provider
SYDNEY and NASHVILLE, Tenn., June 29, 2023 /PRNewswire/ -- IVFAustralia, an Australian-based provider of full-service fertility care, IVF and related services as part of the Virtus Health network, and Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions supporting the life sciences, reproductive medicine and animal health industries, today announced that IVFAustralia has selected Cryoport as its exclusive supply chain solutions partner for its global reproductive material shipments.
May 04, 2023 04:05 pm ET
Cryoport Reports First Quarter 2023 Results
Record revenue of $63 million, representing 20% growth year-over-yearGrowth across all lines of business: Biopharma/Pharma revenue up 19%; Animal Health revenue up 30%; Reproductive Medicine revenue up 13% year-over-yearCommercial Cell and Gene Therapy revenue up 28% year-over-year, now supporting 82 Phase 3 clinical trialsStrong balance sheet with $523 million in cash and short-term investmentsNASHVILLE, Tenn., May 4, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the
Apr 27, 2023 08:30 am ET
Cryoport to Report First Quarter 2023 Financial Results on May 4, 2023
NASHVILLE, Tenn., April 27, 2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences, reproductive medicine and animal health industries, today announced that the Company will report financial results for the first quarter ended March 31, 2023 on Thursday, May 4, 2023 after U.S. markets close.
Apr 25, 2023 08:30 am ET
Cryoport Signs New Supply Chain Solutions Agreement with Boston IVF to Support Reproductive Material Shipments Across the U.S.
NASHVILLE, Tenn., April 25, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences, reproductive medicine and animal health industries, today announced that it has signed a new three-year agreement with Boston IVF, a pioneer in reproductive healthcare and innovative research and one of the world's most experienced fertility treatment providers.
Mar 28, 2023 08:30 am ET
Cryoport Announces Multi-Year Agreement with Inception Fertility
Cryoport to Support The Prelude Network® and MyEggBank®'s Reproductive Material Shipments with its end-to-end supply chain solutions
Mar 13, 2023 06:00 am ET
Cryoport Confirms No Financial Exposure to Silicon Valley Bank
NASHVILLE, Tenn., March 13, 2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences industry, with focus on the bio-pharmaceutical and cell and gene therapy markets, today confirms that the Company does not have any exposure or business relationship with Silicon Valley Bank.  Cryoport does not hold any deposits or securities or maintain any accounts at Silicon Valley Bank or with SVB Securities nor does the Company have a lending or other financial relationshi
Feb 23, 2023 03:05 pm ET
Cryoport Reports Fourth Quarter and Full Year 2022 Results
2022 revenue reached a record $237 million, commercial revenue up 27% year-over-yearNow supporting a record 654 global clinical trials and 10 commercial therapiesEntering 2023 with $523 million in cash and short-term investmentsRevenue guidance for the full year 2023 of $270 - $290 million, up 18% year-over-year at the mid-pointNASHVILLE, Tenn., Feb. 23, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences industry, with focus on the bio-pharmaceutical and
Jan 18, 2023 07:30 am ET
Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies
Partnership to Provide Cell and Gene Industry Integrated Solution including Cryoport's IntegriCell™ platform, and Supply Chain Services
Dec 20, 2022 07:30 am ET
Cryoport to Present at the J.P. Morgan 41st Annual Healthcare Conference
NASHVILLE, Tenn., Dec. 20, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Jerrell Shelton, the Company's Chief Executive Officer, will be presenting at the J.P. Morgan 41st Annual Healthcare conference, taking place from January 9 - 12, 2023 in San Francisco, CA.  Mr. Shelton will be presenting on Thursday, January 12, 2023, at 8:15 a.m. PT (11:15 a.m. ET). Additionally, Mr. Shelton, Robert Stefanovich, the Company's Chief Financial Officer
Nov 03, 2022 04:05 pm ET
Cryoport Reports Results for the Third Quarter 2022
Third quarter revenue of $60.5 million; nine months 2022 revenue reaches $176.9 million; Cryoport Systems' revenue up 25% year-over-year $530 million in cash and short-term investmentsSupporting a record 643 global clinical trials; 61 net new trials added (year-over-year)Entered strategic relationship with Takeda's BioLife Plasma Services for apheresis collection and leukopak productionRecord number of new products and offerings slated to be released by Cryoport in 2023 NASHVILLE, Tenn.,  Nov. 3, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leade
Oct 27, 2022 08:30 am ET
Cryoport to Report Third Quarter 2022 Financial Results on November 3, 2022
NASHVILLE, Tenn., Oct. 27, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the three months period ended September 30, 2022 (third quarter 2022) on Thursday, November 3, 2022 after U.S. markets close.
Sep 08, 2022 08:30 am ET
Cryoport Enters into Strategic Relationship with Takeda's BioLife Plasma Services
Cryoport plans to establish an integrated supply chain platform with BioLife Plasma Services to offer standardized cell therapy collection, processing, and storage services in United States and Europe over time
Aug 04, 2022 04:05 pm ET
Cryoport Reports Results for the Second Quarter 2022
Record revenue of $64.2 million for the quarter, up 14% as reported and 18% at constant currency (year-over-year)Supporting a record 626 global clinical trials; a net of 17 new trials added during the quarter Opened first two Global Supply Chain Centers, which include BioServices, in June 2022Expanded global footprint into Spain and Ireland NASHVILLE, Tenn., Aug. 4, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- a
Jul 28, 2022 08:30 am ET
Cryoport to Report Second Quarter 2022 Financial Results on August 4, 2022
NASHVILLE, Tenn., July 28, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the three months period ended June 30, 2022 (second quarter 2022) on Thursday, August 4, 2022 after U.S. markets close.
May 05, 2022 04:05 pm ET
Cryoport Reports First Quarter 2022 Results
Revenue of $52.3 million Provides Full Year 2022 Revenue Guidance of $260-$265 millionExpansion and advancement of robust clinical pipeline continues – now supporting a record 609 clinical trials, with Phase 3 clinical trials increasing from 69 to 81 year over yearCash and short-term investments of $600 millionNASHVILLE, Tenn., May 5, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three months ended March 31, 2022.
Apr 28, 2022 08:30 am ET
Cryoport to Report First Quarter 2022 Financial Results on May 5, 2022
NASHVILLE, Tenn., April 28, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the three months period ended March 31, 2022 (first quarter 2022) on Thursday, May 5, 2022 after U.S. markets close.
Apr 18, 2022 08:30 am ET
Cryoport Acquires Cell&Co BioServices
Acquisition of Cell&Co BioServices, Clermont-Ferrand, France, accelerates Company's EMEA expansion plans and development of its Global Supply Chain Network
Mar 30, 2022 05:00 pm ET
Cryoport's MVE Biological Solutions' New Prague Manufacturing Plant Returns to Full Production
      Company provides further update on financial impact of New Prague, MN fire
Mar 11, 2022 02:40 pm ET
Cryoport Authorizes $100 Million Repurchase Program
Management Presenting at Upcoming Investor Conferences
Feb 24, 2022 03:05 pm ET
Cryoport Reports Fourth Quarter and Full Year 2021 Results
NASHVILLE, Tenn., Feb. 24, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three months and year ended December 31, 2021.
Feb 15, 2022 07:30 am ET
Cryoport Report's Fourth Quarter and 2021 Financial Results on February 24, 2022
NASHVILLE, Tenn., Feb. 15, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2021 on Thursday, February 24, 2022 after U.S. markets close.
Feb 09, 2022 08:29 am ET
Cryoport Provides Positive Update on MVE Biological Solution's New Prague Facility
NASHVILLE, Tenn., Feb. 9, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today provided an update on resumption of activities at the New Prague facility. As previously announced, a fire occurred in a portion of the MVE Biological Solutions manufacturing facility located in New Prague, Minnesota on January 25, 2022, causing production to be temporarily curtailed. The New Prague facility manufactures aluminum dewars and is one of MVE Biological Solutions' three gl
Jan 31, 2022 04:35 pm ET
Cryoport Reports Fire Damage at MVE's New Prague Facility
NASHVILLE, Tenn., Jan. 31, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today reports that on January 25, 2022, a fire occurred at the MVE Biological Solutions manufacturing facility located in New Prague, Minnesota. The New Prague facility manufactures aluminum dewars and is one of MVE Biological Solutions' three global manufacturing facilities. There were no injuries reported and damage was limited to a portion of the facility.
Jan 27, 2022 07:30 am ET
Cryoport and Cell Matters Enter into Strategic Partnership
NASHVILLE, Tenn., Jan. 27, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that it has entered into a strategic partnership with Cell Matters, S.A. to deliver to the life sciences industry end-to-end cryopreservation services for leukapheresis derived therapies supporting both autologous and allogeneic cell therapies. The companies will jointly develop the commercial approach for marketing these services.
Jan 05, 2022 07:30 am ET
Cryoport to Present at the J.P. Morgan 40th Annual Healthcare Conference
NASHVILLE, Tenn., Jan. 5, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Jerrell Shelton, the Company's Chief Executive Officer and Robert Stefanovich, the Company's Chief Financial Officer will be presenting at the J.P. Morgan 40th Annual Healthcare conference taking place virtually from January 10 - 13, 2022.  Mr. Shelton will be presenting on Wednesday, January 12, 2022, at 9:00 a.m. ET. Additionally, Mr. Shelton, Mr. Stefanovich, and Tho
Nov 09, 2021 11:20 pm ET
Cryoport, Inc. Prices Registered Direct Placement of Common Stock
NASHVILLE, Tenn., Nov. 9, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the pricing of its registered direct placement of 3,072,038 shares of common stock, at a price of $81.10 per share, in a direct placement registered under the Securities Act of 1933, as amended. The issuance and sale of the common stock are scheduled to settle on November 12, 2021, subject to customary closing conditions.
Nov 09, 2021 11:20 pm ET
Cryoport, Inc. Prices Upsized $350.0 Million Convertible Senior Notes Offering
NASHVILLE, Tenn., Nov. 9, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the pricing of its offering of $350,000,000 aggregate principal amount of 0.75% convertible senior notes due 2026 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased from the previously announced offering size of $300,000,000 aggregate principal amount of notes. The
Nov 08, 2021 03:33 pm ET
Cryoport, Inc. Announces Proposed Convertible Senior Notes Offering
NASHVILLE, Tenn., Nov. 8, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its intention to offer, subject to market and other conditions, $300,000,000 aggregate principal amount of convertible senior notes due 2026 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Cryoport also expects to grant the initial purchasers of the notes an option to purchase, for settlement
Nov 08, 2021 03:29 pm ET
Cryoport, Inc. Announces Proposed Registered Direct Placement of Common Stock
NASHVILLE, Tenn., Nov. 8, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its intention to offer, subject to market and other conditions, shares of its common stock in a direct placement registered under the Securities Act of 1933, as amended. The number of shares to be sold, and the price per share, will be determined at the pricing of the placement.
Nov 04, 2021 04:05 pm ET
Cryoport Reports Record Third Quarter and Nine Months Revenue for 2021
NASHVILLE, Tenn., Nov. 4, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and nine-month periods ended September 30, 2021.
Oct 29, 2021 10:30 am ET
CRYOPDP, a Cryoport Company, Receives 2021 Europe Bioprocessing Excellence Award from IMAPAC
NASHVILLE, Tenn., Oct. 29, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that its wholly-owned operating company, CRYOPDP, a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, biopharmaceutical and cell and gene therapy markets, headquartered in Paris, France has been recognized as winner of the award, 'The Company You Need to Watch Out For in 2022' at the Europe Bioprocessing Excellence Aw
Oct 28, 2021 04:15 pm ET
Cryoport to Report Third Quarter 2021 Financial Results on November 4, 2021
NASHVILLE, Tenn., Oct. 28, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2021 on Thursday, November 4, 2021 after U.S. markets close. 
Aug 25, 2021 08:15 am ET
Cryoport and Mitsubishi Logistics Corporation Partner to Bring Temperature-Controlled Supply Chain Solutions to Asia-Pacific
NASHVILLE, Tenn., Aug. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences including clinical research, pharmaceutical and cell and gene therapy markets, and Mitsubishi Logistics Corporation ("MLC"), Japan's leading pharma logistics company, today announced a multi-year strategic business alliance to create an integrated regenerative medicine supply chain partnership in Japan.
Aug 05, 2021 04:05 pm ET
Cryoport Reports Record Second Quarter 2021 Revenue
NASHVILLE, Tenn., Aug. 5, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and six-month periods ended June 30, 2021.
Jul 29, 2021 08:30 am ET
Cryoport to Report Second Quarter 2021 Financial Results on August 5, 2021
NASHVILLE, Tenn., July 29, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the second quarter ended June 30, 2021 on Thursday, August 5, 2021 after U.S. markets close. 
Jun 22, 2021 08:30 am ET
Cellenkos® Selects Cryoport to Support On-Demand, Flexible COVID-19 Therapy Shipments to Patients in Need
NASHVILLE, Tenn., June 22, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Cellenkos®, Inc., a privately held, clinical-stage biotechnology company, has selected Cryoport to provide a staged, on-demand, logistics solution for COVID-19 therapy shipments for patients in need.
Feb 25, 2021 07:45 am ET
Cryoport to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 1, 2021
NASHVILLE, Tenn., Feb. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth quarter and fiscal year ended December 31, 2020 on Monday, March 1, 2021 after U.S. markets close.
Feb 25, 2021 07:15 am ET
Cryoport Launches Environmental, Social, and Governance (ESG) Program
NASHVILLE, Tenn., Feb. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the launch of its Environmental, Social & Governance (ESG) initiative – formalizing its long-standing commitment to taking positive action on global environmental, social, health and corporate stewardship issues.
Feb 08, 2021 07:00 am ET
Blackstone Converts $51 million of Cryoport Series C Preferred Stock Into Common Stock
NASHVILLE, Tenn., Feb. 8, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that funds affiliated with Blackstone Tactical Opportunities (NYSE: BX) ("Blackstone"), elected to convert 50,000 shares of 4.0% Series C Convertible Preferred Stock of Cryoport ("Preferred Stock") into common stock of Cryoport pursuant to the Preferred Stock certificate of designations.  The 50,000 shares are a part of the 250,000 shares of Preferred Stock that were origina
Jan 25, 2021 11:22 am ET
Cryoport Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters to Purchase Additional Shares
NASHVILLE, Tenn., Jan. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the closing of an underwritten public offering of 4,356,059 shares of its common stock, at a public offering price of $66.00 per share, which includes 568,181 shares issued following the full exercise by the underwriters of their option to purchase additional shares at the public offering price, before deducting underwriting discounts and commissions.
Jan 20, 2021 09:30 pm ET
Cryoport Announces Pricing of Public Offering of Common Stock
NASHVILLE, Tenn., Jan. 20, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the pricing of its underwritten public offering of an aggregate of 3,787,878 newly issued shares of common stock at a public offering price of $66.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 568,181 shares of common stock. The net proceeds to the Company from the offering of the shares are expected to b
Jan 19, 2021 04:02 pm ET
Cryoport Announces Proposed Public Offering of Common Stock
NASHVILLE, Tenn., Jan. 19, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that it intends to offer $200 million of shares of common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Cryoport also expects to grant the underwriters a 30-day option to purchase up to an a
Dec 08, 2020 07:30 am ET
Cryoport and CCRM Fertility Enter Into Agreement
NASHVILLE, Tenn., Dec. 8, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced a three-year agreement with the Colorado Center for Reproductive Medicine ("CCRM"), a global pioneer in fertility science, research and advancement. Under the terms of the agreement, Cryoport's temperature-controlled solutions will support CCRM's fertility treatments, including in vitro fertilization (IVF), fertility preservation, third-party reproduction and egg donation.
Nov 05, 2020 03:05 pm ET
Cryoport Reports 2020 Third-Quarter Results
NASHVILLE, Tenn., Nov. 5, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport", "our" or "we"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, announced financial results for the Third Quarter and nine-month period ended September 30, 2020.
Oct 29, 2020 02:15 pm ET
Cryoport to Report Third Quarter 2020 Financial Results on November 5, 2020
NASHVILLE, Oct. 29, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in life sciences solutions, today announced that the Company will report financial results for the third quarter ended September 30, 2020 on Thursday, November 5, 2020 after U.S. markets close. 
Oct 01, 2020 11:38 am ET
Chart Industries Expands Liquid Hydrogen and LNG Business with Strategic Agreements
Chart Industries, Inc. (“Chart”) (NASDAQ: GTLS) today completed the previously announced divestiture of its cryobiological products business (MVE Biological Products) to Cryoport, Inc. (“Cryoport”) (NASDAQ: CYRX) for $320 million in cash. On...
Aug 06, 2020 04:05 pm ET
Cryoport Reports 2020 Second-Quarter Results
NASHVILLE, Tenn., Aug. 6, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in life sciences supply chain solutions, today announced financial results for Second Quarter and six-month period ended June 30, 2020.
Aug 04, 2020 08:30 am ET
MEDIPAL HOLDINGS Partners with CRYOPORT to Bring Temperature-Controlled Supply Chain Solutions to the Japanese Market
NASHVILLE, Tenn. and TOKYO, Aug. 4, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in life sciences supply chain solutions, and MEDIPAL HOLDINGS CORPORATION (7459:JP), ("MEDIPAL") Japan's leading pharma wholesaler and distributor today announced a multi-year strategic business alliance agreement to create an integrated regenerative medicine supply chain solution in Japan.
Aug 03, 2020 04:10 pm ET
Cryoport to Report Second Quarter 2020 Financial Results on August 6, 2020
NASHVILLE, Tenn., Aug. 3, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in life sciences solutions, today announced that the Company will report financial results for the second quarter ended June 30, 2020 on Thursday, August 6, 2020 after U.S. markets close. 
May 21, 2020 07:00 am ET
Cryoport, Inc. Prices $100.0 Million Convertible Senior Notes Offering
NASHVILLE, Tenn., May 21, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport") today announced the pricing on May 20, 2020 of its offering of $100.0 million in aggregate principal amount of 3.00% convertible senior notes due 2025 (the "notes") in a private offering to investors reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").  Cryoport also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $15.0 million in principal amount of notes.
May 19, 2020 06:54 pm ET
Cryoport, Inc. Announces Proposed Convertible Senior Notes Offering
NASHVILLE, Tenn., May 19, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport") today announced its intention to offer, subject to market and other conditions, $100.0 million in aggregate principal amount of convertible senior notes due 2025 (the "notes") in a private offering to investors reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Cryoport also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $15.0 million in principal amount
May 07, 2020 07:50 pm ET
/C O R R E C T I O N -- Cryoport, Inc./
In the news release, Cryoport Revenue Grows 47% for First Quarter 2020, issued 07-May-2020 by Cryoport, Inc. over PR Newswire, we are advised by the company that in the Consolidated Balance Sheets, at the end of the release, operating lease liabilities, net, should be $5,568,845; Total liabilities should be $12,818,304 and Total liabilities and stockholders' equity should be $140,123,251. The complete, corrected release follows:
May 07, 2020 04:05 pm ET
Cryoport Revenue Grows 47% for First Quarter 2020
NASHVILLE, Tenn., May 7, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), a global leader in life sciences solutions, today announced financial results for the three-month period ended March 31, 2020.
Apr 30, 2020 08:30 am ET
Cryoport to Report First Quarter 2020 Financial Results on May 7, 2020
NASHVILLE, Tenn., April 30, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), a global leader in life sciences solutions, today announced that the Company will report financial results for the first quarter ended March 31, 2020 on Thursday, May 7, 2020 after U.S. markets close. 
Nov 07, 2019 03:05 pm ET
Cryoport Revenue Grows 81% for Third Quarter 2019
IRVINE, Calif., Nov. 7, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced financial results for the three and nine-month periods ended September 30, 2019.
Nov 05, 2019 08:00 am ET
Oct 31, 2019 08:30 am ET
Cryoport to Report Third Quarter 2019 Financial Results on November 7, 2019
IRVINE, Calif., Oct. 31, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2019 on Thursday, November 7, 2019 after U.S. markets close.
Oct 09, 2019 09:00 am ET
Cryoport Authorizes Share Repurchase Program and Presenting at Upcoming Investor Conferences
IRVINE, Calif., Oct. 9, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the life sciences industry, today announced its Board of Directors has unanimously authorized a share repurchase program, under which Cryoport may repurchase up to $15 million of its outstanding common stock.
Oct 09, 2019 08:00 am ET
Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the life...
Sep 18, 2019 08:30 am ET
Cryoport Introduces Cell & Gene Industry's First Dedicated Shipper for Advanced Therapies
IRVINE, Calif., Sept. 18, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the life sciences industry, today announced the launch of its Advanced Therapy Shipper™ product line for the regenerative medicine market. The Advanced Therapy Shipper™ guarantees each shipper has been used only for human use and provide complete traceability of all equipment, components and commodities.  The result is unmatched verification information and unmatched supply chain support for biopharma co
Sep 04, 2019 08:00 am ET
Vineti and Cryoport Collaborate to Bring Integrated Solutions to the Global Regenerative Therapy Market
Vineti, Inc., and  Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) announced a commercial partnership designed to extend end-to-end delivery of cell therapies and gene therapies to a growing number of patients as the industry continues to scale....
Aug 12, 2019 06:30 am ET
BriaCell Appoints Richard J. Berman to Board of Directors
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that it has appointed Mr. Richard J....
Aug 08, 2019 04:05 pm ET
Cryoport Revenue Grows 83% for Second Quarter 2019
IRVINE, Calif., Aug. 8, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced financial results for the three and six-month periods ended June 30, 2019.
Jul 25, 2019 08:30 am ET
Cryoport to Report Second Quarter 2019 Financial Results on August 8th, 2019
IRVINE, Calif., July 25, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the second quarter ended June 30, 2019 on Thursday, August 8, 2019 after U.S. markets close. 
Jul 11, 2019 08:30 am ET
Cryoport and EVERSANA Form Strategic Alliance to Accelerate Regenerative Medicine Supply Chain
IRVINE, Calif., July 11, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) and EVERSANA™ have announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution. The alliance will be designed to leverage EVERSANA's position as the leading provider of commercial services addressing access, affordability and adherence challenges for cell and gene therapies and Cryoport's complete suite of temperature-controlled logistics solutions to ensure a safe and effective supply chain solution for innovative therapeutic advancements.  
May 16, 2019 08:00 am ET
CalAmp Announces Research Collaboration with Cryoport to Develop Next Generation Condition Monitoring System
IRVINE, Calif., May 16, 2019 /PRNewswire/ -- CalAmp (Nasdaq: CAMP), an advanced technology solutions pioneer transforming the global connected economy, today announced a strategic collaboration with Cryoport (Nasdaq: CYRX) (Nasdaq: CYRXW), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, to develop a next generation condition monitoring system to further assure the security of global temperature controlled pharmaceutical shipments.
May 14, 2019 05:22 pm ET
Cryoport Expands into Biostorage through the Acquisition of Cryogene
IRVINE, Calif., May 14, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced that it has expanded its suite of temperature-controlled solutions to include biostorage for the life sciences through its acquisition of Cryogene Partners ("Cryogene"), a Houston-based company. Cryogene operates a recently expanded 21,000 square foot state-of-the-art biostorage facility, specializing in the secure storage of biological specimens, materials and samples. The
May 09, 2019 08:30 am ET
Cryoport to Host Workshop at 14th Annual World Advanced Therapies & Regenerative Medicine Congress on Wednesday, May 15th
IRVINE, Calif., May 9, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, announced today its 2nd annual workshop, titled, 'Process Considerations for Cryogenic and Regenerative Medicine Commercialization,' taking place on Wednesday, May 15, 2019 at the Business Design Centre in London, United Kingdom. The educational workshop is taking place in conjunction with the World Advanced Therapies & Regenerative Medicine Congress event and is aimed at biotechnology
May 02, 2019 04:05 pm ET
Cryoport Revenue Grows 65% for First Quarter 2019
IRVINE, Calif., May 2, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced financial results for the three-month period ended March 31, 2019.
Apr 25, 2019 08:30 am ET
Cryoport to Report First Quarter 2019 Financial Results on May 2nd, 2019
IRVINE, Calif., April 25, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the first quarter ended March 31, 2019 on Thursday, May 2, 2019 after U.S. markets close. 
Apr 11, 2019 08:30 am ET
Celularity Selects Cryoport's Temperature Controlled Logistics Solutions
IRVINE, Calif., April 11, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced it has been selected by Celularity, a world leading allogeneic cell therapy company, to utilize its complete range of temperature-controlled solutions.
Apr 01, 2019 08:10 am ET
Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Verizon Communications Inc. (NYSE:VZ), Digital Turbine, Inc. (NASDAQ:APPS),...
Mar 28, 2019 08:46 am ET
Biokin Pharmaceutical Selects Cryoport's Temperature-Controlled Solutions for its Pending Phase I and Phase II trials
CHENGDU, China and SEATTLE and IRVINE, Calif., March 28, 2019 /PRNewswire/ -- Biokin Pharmaceutical Co. Ltd., ("Biokin Pharma") a leading pharmaceutical company with operations in China and U.S., and Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced Cryoport's full suite of temperature-controlled solutions will support Biokin Pharma's pending Phase I and II clinical trials in immuno-oncology in both the U.S. and China.
Mar 07, 2019 03:05 pm ET
Cryoport Reports 64% Growth for Fiscal Year 2018
IRVINE, Calif., March 7, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced financial results for the three and twelve-month periods ended December 31, 2018.
Feb 26, 2019 07:30 am ET
Cryoport to Report Fourth Quarter and Fiscal Year 2018 Financial Results on March 7th, 2019
IRVINE, Calif., Feb. 26, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world's leading temperature controlled logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the fourth quarter and fiscal year ended December 31, 2018 on Thursday, March 7, 2019 after U.S. markets close. 
Jan 30, 2019 07:30 am ET
Cryoport Opens Global Logistics Center in Amsterdam
IRVINE, Calif., Jan. 30, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today will celebrate the official opening of its most recent Global Logistics Center, based in Amsterdam, The Netherlands. The ribbon-cutting ceremony will be attended by Cryoport clients, governmental dignitaries and business partners. The new Global Logistics Center is located at Parellaan 18, 2132 WS Hoofddorp, near the Schiphol Amsterdam Airport, which serves as The Netherland's main
Jan 14, 2019 07:30 am ET
Dacos A/S Partners with Cryoport to Offer Full Suite of Temperature-Controlled Logistics Solutions to Global Client Base
IRVINE, Calif., Jan. 14, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced it has partnered with Dacos A/S ("Dacos"), a high-tech production company of life sciences products with headquarters in Denmark, to deliver end-to-end temperature-controlled logistics solutions to Dacos' global client base of biopharmaceutical companies.
Jan 07, 2019 07:30 am ET
Cryoport Appoints Daniel M. Hancock to Board of Directors
IRVINE, Calif., Jan. 7, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, is pleased to announce the appointment of Daniel M. (Dan) Hancock to its Board of Directors. Mr. Hancock's appointment adds extensive physics knowledge, engineering and innovation experience, business acumen and leadership to the Board of Directors. Mr. Hancock will serve on the Audit Committee, chaired by Richard Berman, Esq. and the Science and Technology Committee, chaired by Robert Har
Dec 17, 2018 07:30 am ET
Cryoport Announces $25 Million Investment from Petrichor Healthcare Capital Management
IRVINE, Calif., Dec. 17, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or "the Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced the closing of a $25 million investment from Petrichor Healthcare Capital Management ("Petrichor").
Dec 11, 2018 08:10 am ET
Consolidated Research: 2018 Summary Expectations for IRHYTHM TECH, ON Semiconductor, CryoPort, Celcuity, InnerWorkings, and AgroFresh Solutions — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of IRHYTHM TECH (NASDAQ:IRTC), ON Semiconductor Corporation (NASDAQ:ON),...
Nov 08, 2018 03:10 pm ET
Cryoport Revenue Grows 76% for Third Quarter 2018; 91% Growth in Biopharma
IRVINE, Calif., Nov. 8, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced financial results for the three- and nine-month periods ended September 30, 2018.
Oct 30, 2018 08:30 am ET
Cryoport to Report Third Quarter 2018 Financial Results on November 8th, 2018
IRVINE, Calif., Oct. 30, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world's leading temperature controlled logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2018 on Thursday, November 8, 2018 after U.S. markets close.  Cryoport management will host a conference call at 4:30 pm EST on November 8, 2018 to discuss the financial results, review recent corporate developments and provide a general business outlook.
Oct 23, 2018 04:05 pm ET
Cryoport Celebrates Grand Opening of its Global Logistics Center In New Jersey with Ribbon Cutting Ceremony
IRVINE, Calif., Oct. 23, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today unveiled its newest Global Logistics Center, based in Livingston, New Jersey with a ribbon-cutting ceremony attended by several of Cryoport's clients, local dignitaries and business partners. Cryoport's newest state-of-the-art Global Logistics Center is located in a strategic life sciences hub and provides an important addition to Cryoport's logistics network, which allows the Company to
Oct 22, 2018 07:30 am ET
Market Trends Toward New Normal in CryoPort, The J. M. Smucker, Accenture, Albemarle, The Allstate, and Huami — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CryoPort, Inc. (NASDAQ:CYRX), The J. M. Smucker Company (NYSE:SJM),...
Oct 03, 2018 08:00 am ET
Be The Match BioTherapies® and Cryoport Announce Strategic Partnership to Deliver Integrated End-to-End Supply Chain Services to the Cell and Gene Therapy Industry
MINNEAPOLIS, Minn. and IRVINE, Calif., Oct. 3, 2018 /PRNewswire/ -- Be The Match BioTherapies, an organization offering integrated systems and software to manage the collection and delivery of cellular therapies, and Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced a strategic partnership to deliver end-to-end supply chain services to the cell and gene therapy industry. The collaboration will support both organizations' efforts to standardize critical elements of the cell therapy supply
Oct 03, 2018 08:00 am ET
Be The Match BioTherapies® and Cryoport Announce Strategic Partnership to Deliver Integrated End-to-End Supply Chain Services to the Cell and Gene Therapy Industry
Be The Match BioTherapies, an organization offering integrated systems and software to manage the collection and delivery of cellular therapies, and Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced a strategic partnership to deliver end-to-end supply chain services to the cell and gene therapy industry. The collaboration will support both organizations’ efforts to standardize critical elements of the cell therapy supply chain, as well as pr
Aug 09, 2018 04:10 pm ET
Cryoport Revenue Grows 59% for Second Quarter 2018; 73% in Biopharma
IRVINE, Calif., Aug. 9, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced financial results for the three and six-month periods ended June 30, 2018.
Aug 07, 2018 08:30 am ET
Cryoport Launches CryoStork℠ Insurance to Support IVF Logistics Solutions
IRVINE, Calif., Aug. 7, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced the upcoming launch of CryoStork℠ Insurance, which is designed to better serve intended parents and is also in response to the rise in demand for assisted reproductive medicine.
Aug 01, 2018 08:30 am ET
Cryoport to Report Second Quarter 2018 Financial Results on August 9th, 2018
IRVINE, Calif., Aug. 1, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world's leading temperature controlled logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the second quarter ended June 30, 2018 on Thursday, August 9, 2018 after U.S. markets close.  Cryoport's senior management will host a conference call at 4:30 pm ET on August 9, 2018 to discuss the financial results, review recent corporate developments and provide a general business outlook.
Jul 16, 2018 08:30 am ET
Cryoport Partners with World Courier to Provide Best-In-Class Logistics Platform for Global Cell and Gene Therapy Market
IRVINE, Calif., July 16, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), today announced that World Courier, a part of AmerisourceBergen, will integrate Cryoport's full suite of temperature-controlled solutions into its global network.  This integrated platform offers complete Chain of Compliance™ solutions for biopharmaceutical companies, ensuring full traceability of equipment, processes, and handling of cell and gene therapies while in transit.
Jun 29, 2018 04:43 pm ET
Cryoport Delivers Biological Samples for International Space Station; Rocket Launched Today Arrives at International Space Station on Monday
IRVINE, Calif., June 29, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading temperature controlled logistics company dedicated to the life sciences industry, announced that biological samples transported by Cryoport were launched today at 5:42 am EDT on SpaceX's Falcon 9 rocket which took off from Cape Canaveral in Florida to the International Space Station (ISS).
Jun 11, 2018 08:30 am ET
Cryoport Set to Join Russell 3000 Index and Russell 2000 Index
IRVINE, Calif., June 11, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), the global leader in temperature-controlled logistics dedicated to the life sciences industry, today announced it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective after the US market opens on June 25th, according to a preliminary list of additions posted June 8th.
May 03, 2018 04:10 pm ET
Cryoport Revenue Grows 48% for First Quarter; 62% in Biopharma
IRVINE, Calif., May 3, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), the global leader in temperature-controlled logistics dedicated to the life sciences industry, today announced financial results for the three-month period ended March 31, 2018.
Apr 23, 2018 08:30 am ET
Cryoport to Report First Quarter 2018 Financial Results on May 3rd, 2018
IRVINE, Calif., April 23, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the global leader in temperature-controlled logistics dedicated to the life sciences industry, today announced that the Company will report financial results for the first quarter ended March 31, 2018 on Thursday, May 3, 2018 after U.S. markets close.  Cryoport's senior management will host a conference call at 4:30 pm ET on May 3, 2018 to discuss the financial results, review recent corporate developments and provide a general business outlook.
Mar 06, 2018 03:10 pm ET
Cryoport Reports 56% Revenue Growth for Fiscal Year Ended December 31, 2017
IRVINE, Calif., March 6, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), the global leader in temperature-controlled logistics dedicated to the life sciences industry, today announced financial results for the three and twelve-month periods ended December 31, 2017.
Feb 26, 2018 09:00 am ET
McKesson Specialty Health and Cryoport Collaborate to Bolster Logistics Services to Support Commercialization of Cell and Gene Therapies
McKesson Specialty Health, a division of McKesson Corporation, announced a strategic collabor
Feb 20, 2018 07:30 am ET
Cryoport to Report Fourth Quarter and Fiscal Year 2017 Financial Results on March 6th, 2018
IRVINE, Calif., Feb. 20, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world's leading temperature controlled logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the fourth quarter and fiscal year ended December 31, 2017 on Tuesday, March 6, 2018 after U.S. financial markets close.  Cryoport's senior management will host a conference call at 4:30 pm ET on March 6, 2018 to discuss the financial results, review recent corporate developments and provide a general bu
Feb 15, 2018 07:30 am ET
Cryoport to Provide DiscGenics with Cutting Edge Cold Chain Logistics Support for its Phase 1/2 Trial
IRVINE, Calif., Feb. 15, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), (NASDAQ: CYRXW) ("Cryoport" or the "Company"), the world's leading temperature controlled logistics company dedicated to the life sciences industry, today announced it has been selected by DiscGenics to provide logistics support to its multicenter, first-in-human study to evaluate the safety and preliminary efficacy of IDCT, its allogeneic injectable cell therapy, in patients with single level, symptomatic lumbar intervertebral disc degeneration.
Feb 05, 2018 07:30 am ET
Cryoport To Provide TiGenix With Cutting Edge Cold Chain Logistics for Clinical Trial of SEPCELL for the Treatment of Sepsis
IRVINE, Calif., Feb. 5, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading temperature controlled logistics company dedicated to the life sciences industry, today announced that Cryoport will support TiGenix (Euronext Brussels and NASDAQ: TIG) as it conducts its SEPCELL phase Ib/IIa clinical study to evaluate the safety and efficacy of expanded Cx611 allogeneic adipose‐derived stem cells (eASCs) for the treatment of sepsis in adult patients with severe community‐acquired bacterial pneumonia and admitted to the intensive care unit.
Dec 18, 2017 07:30 am ET
The Cryoport Biotech Activity Index Decreases 7.1% In Third Quarter of 2017; While the Total Number of Clinical Trials Increases to 934 Worldwide
IRVINE, Calif., Dec. 18, 2017 /PRNewswire/ -- The Cryoport Biotech Activity Index (the "CoBRA IndexSM"), which quantifies the activity in the development and clinical trials of regenerative therapies in the United States, decreased 7.1% to 222 in the third quarter of 2017. However, the regenerative market space continues to show robustness with the number of clinical trials increasing from 899 to 934, as reported by the Alliance for Regenerative Medicine. The CoBRA Index SM acts as a means by which investors, the media and industry participants can evaluate investment in the space by viewing
Nov 02, 2017 05:10 pm ET
Cryoport Revenue Up 52%; Driven by BioPharma
IRVINE, Calif., Nov. 2, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced financial results for the three- and nine-month periods ended September 30, 2017.
Oct 26, 2017 05:10 pm ET
Cryoport to Report Third Quarter 2017 Financial Results on November 2nd, 2017
IRVINE, Calif., Oct. 26, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2017 on Thursday, November 2, 2017 after U.S. financial markets close.  Cryoport's senior management will host a conference call at 4:30 pm ET on November 2, 2017 to discuss the financial results, review recent corporate developments and provide a general business outlook.
Oct 26, 2017 09:30 am ET
Cryoport Launches New Website for CryoStork Cryogenic Logistics Solutions for the Reproductive Health Market
IRVINE, Calif., Oct. 26, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the world's leading cold chain logistics company serving the life sciences industry, today announced the launch of a new website supporting its CryoStork(SM) cryogenic logistics solutions offering for the Reproductive Health Market, located at www.myCryoStork.com. Cryoport's CryoStorkSM solutions are revolutionary as they are the fastest, most reliable solutions on the market for Reproductive Health patients, providing express transportation worldwide for commodities such as embr
Oct 05, 2017 09:30 am ET
Cryoport Biotech Activity Index, "CoBRA Index", Increases 8.6% In Second Quarter of 2017
IRVINE, Calif., Oct. 5, 2017 /PRNewswire/ -- The Cryoport Biotech Activity Index (the "CoBRA IndexSM"), which quantifies the activity in the development and clinical trials of regenerative therapies in the United States, increased 8.6% to 239 in the second quarter of 2017. The CoBRA IndexSM acts as a means by which investors, the media and industry participants can evaluate investment in the space.  The Q2 increase reflects the broad and continued growth in the regenerative therapy market.
Oct 02, 2017 09:30 am ET
Cryoport to Provide Nohla Therapeutics with Cutting Edge Cold Chain Logistics to Support Clinical Programs
IRVINE, Calif., Oct. 2, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced that Cryoport will provide its leading edge cold chain logistics solutions to support Nohla Therapeutics' clinical studies evaluating its universal donor cell therapy, NLA101, in patients with hematologic malignancies and other critical diseases. Cryoport's solutions help companies increase their ability to supply product for clinical trials.
Sep 05, 2017 09:30 am ET
Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma's CAR-T Therapy Axicabtagene Ciloleucel
IRVINE, Calif., Sept. 5, 2017 /PRNewswire/ -- Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), today announced that Kite Pharma has chosen Cryoport's industry-leading, advanced technology suite of cryogenic logistics solutions for the life sciences industry to support the potential commercial launch of its lead chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel), for the treatment of aggressive Non-Hodgkin Lymphoma (NHL).  The engagement is structured to support Kite throughout the lifecycle of axi-cel.
Aug 15, 2017 09:45 am ET
Cryoport Launches - Cryoport. Certified. Cool.
IRVINE, Calif., Aug. 15, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced it has expanded its portfolio of cold chain logistics solutions with the launch of its 'Cryoport. Certified. Cool.' solution, which will be branded as "C3 ™", in support of the new high value regenerative therapies that require temperature-controlled transportation within the 2 - 8°C temperature range during the logistics of processing these new therapies.
Aug 08, 2017 05:10 pm ET
Cryoport Revenue Up 52% for the Second Quarter of 2017, Driven by Biopharma
IRVINE, Calif., Aug. 8, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced financial results for the three and six-month periods ended June 30, 2017.
Jul 25, 2017 08:00 am ET
Cryoport to Support Launch of Potential Treatment for Relapsed/Refractory Acute Lymphoblastic Leukemia
IRVINE, Calif., July 25, 2017 /PRNewswire/ -- Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), today announced that Novartis has signed an agreement contracting Cryoport over an initial three-year term for cryogenic logistics support of CTL019/CD19 CAR-T cell therapy.
Jul 24, 2017 09:30 am ET
Cryoport to Report Second Quarter 2017 Financial Results on August 8th, 2017
IRVINE, Calif., July 24, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the second quarter ended June 30, 2017 on Tuesday, August 8, 2017 after U.S. markets close. Cryoport's senior management will discuss the financial results, review recent corporate developments and provide a general business outlook.
Jul 13, 2017 09:58 am ET
Cryoport Continues to Strengthen Sales Team with Appointments of Colin Coffua as Vice President, Strategic Accounts and John Phillips as Executive Director, Consulting Services
IRVINE, Calif., July 13, 2017 /PRNewswire/ -- Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced it has strengthened its sales team with the appointments of Colin Coffua as Vice President, Strategic Accounts and John Phillips as Executive Director, Consulting Services.
Jun 19, 2017 09:30 am ET
Cryoport Biotech Activity Index "CoBRA Index" increases 30.1% in Q1 2017
IRVINE, Calif., June 19, 2017 /PRNewswire/ -- The Cryoport Biotech Activity Index (the "CoBRA IndexSM") quantifies the activity in the development and clinical trials of regenerative therapies in the United States, and acts as a means by which investors, the media and industry participants can evaluate investment in the space. The CoBRA IndexSM was launched in February by Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the world's leading cold chain logistics solutions provider dedicated to the life sciences industry.
Jun 07, 2017 09:30 am ET
Cryoport Expands Agreement with Sanaria to Support Grant Awards with U.S. National Institutes of Health and U.S. Army
IRVINE, Calif., June 7, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading cryogenic logistics company dedicated to the life sciences industry, announces that it will assist Sanaria Inc. in the design and implementation of the cryogenic cold chain for Sanaria's investigational malaria vaccines.  This work is supported by grants to Sanaria from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) (phase II Commercialization Readiness Pilot Program) and U.S. Department of Defense (DoD) (phase I Small Business Innovat
May 04, 2017 05:10 pm ET
Cryoport Revenue Grows by 74%, Driven by Biopharma
IRVINE, Calif., May 4, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced financial results for the first quarter ended March 31, 2017.
Apr 24, 2017 09:30 am ET
Cryoport to Report First Quarter 2017 Financial Results on May 4th, 2017
IRVINE, Calif., April 24, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the first quarter ended March 31, 2017 on Thursday, May 4, 2017 after U.S. markets close.  Cryoport's senior management will discuss the financial results, review recent corporate developments and provide a general business outlook.
Mar 28, 2017 10:30 am ET
Cryoport Announces Pricing of Public Offering of Common Stock
IRVINE, Calif., March 28, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company") today announced the pricing of its underwritten public offering of an aggregate of 5,500,000 newly issued shares of common stock at a price of $2.00 per share. The underwriters have also been granted a 30-day option to purchase up to 825,000 shares of common stock to cover over-allotments, if any. The net proceeds to the Company from the offering of the shares are expected to be approximately $9.9 million after deducting estimated underwriting discounts and commissions and offeri
Mar 27, 2017 05:12 pm ET
Cryoport Announces Proposed Public Offering of Common Stock
IRVINE, Calif., March 27, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company") today announced that it intends to offer shares of common stock in an underwritten public offering under an effective shelf registration statement on file with the Securities and Exchange Commission (the "SEC"). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Cryoport also expects to grant the underwriters a 30-day option to purchase up to
Mar 13, 2017 05:05 pm ET
Cryoport Revenue Continues to Climb, Reporting 53% Growth for the Quarter Ended December 31, 2016
IRVINE, Calif., March 13, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW), ("Cryoport" or the "Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced financial results for the three and nine-month periods ended December 31, 2016. The nine-month period ended December 31, 2016 constitutes the abridged fiscal year from April 1, 2016 to December 31, 2016, as a result of the Company changing its fiscal year end from March 31 to December 31.
Mar 02, 2017 08:30 am ET
Cryoport to Report Financial Results for the Three and Nine Months Ended December 31, 2016 on March 13th, 2017
IRVINE, Calif., March 2, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the three and nine month periods ended December 31, 2016 on Monday, March 13, 2017 after U.S. markets close. Cryoport's senior management will discuss the financial results, review recent corporate developments and provide a general business outlook.
Mar 01, 2017 08:28 am ET
Cryoport Introduces CryoStork Next Flight Out Cryogenic Logistics Solution for the Reproductive Health Market
IRVINE, Calif., March 1, 2017 /PRNewswire/ -- Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced the launch of CryoStorkSM Next Flight Out for the reproductive health market. CryoStorkSM Next Flight Out is the fastest, most reliable solution on the market for reproductive health patients, providing express transportation across the United States and the world for reproductive health commodities such as sperm, eggs, embryos and reproductive tissues.
Feb 28, 2017 08:30 am ET
Cryoport Launches the "CoBRA Index" for a Comprehensive Measure of Activity in the Regenerative Therapy Space
IRVINE, Calif., Feb. 28, 2017 /PRNewswire/ -- For the first time, there is a way to measure relative activity in the regenerative therapy space on a quarterly basis. The Cryoport Biotech Regenerative Therapy Activity Index (the "CoBRA IndexSM") quantifies the activity in the development and clinical trials of regenerative therapies in the United States, and acts as a means by which investors, the media and industry participants can use the Index to help evaluate investment in the space. The CoBRA IndexSM is being launched by Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"),
Jan 17, 2017 08:30 am ET
Cryoport to Support ProMab Biotechnologies' CAR-T Cell Preclinical Services
IRVINE, Calif., Jan. 17, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the world's leading cryogenic logistics company supporting the life sciences industry, announced today that it will be providing its advanced cryogenic logistics solutions to support ProMab Biotechnologies' ("ProMab") new chimeric-antigen receptors (CARs), and specifically CAR-redirected T-cells (CAR-T).
Jan 03, 2017 08:30 am ET
Cryoport Supports Gradalis' Vigil® Platform in Clinical Trials for Autologous Immunotherapies for Multiple Cancers
IRVINE, Calif., Jan. 3, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading cryogenic logistics company committed to providing innovative, reliable and efficient logistics solutions to the life sciences industry, today announced that its validated cryogenic logistics solutions are supporting Gradalis, Inc.'s clinical trials to evaluate its investigational Vigil® Engineered Autologous Tumor Cell (EATC) cellular immunotherapy technology for use in cancer treatments. Cryoport is currently supporting Gradalis' phase 2/3 trial for high risk stage III/IV ovarian cancer p
Dec 21, 2016 08:30 am ET
Moffitt Cancer Center Taps Cryoport As Exclusive Cryogenics Logistics Provider
TAMPA, Fla., Dec. 21, 2016 /PRNewswire/ -- Moffitt Cancer Center has tapped Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or "the Company"), the world's leading cryogenic logistics company, to provide support for its immunology program, cancer research, and therapy programs and lab moves.
Nov 14, 2016 04:05 pm ET
Cryoport Reports 38% Revenue Growth for the Second Quarter of Fiscal Year 2017
IRVINE, Calif., Nov. 14, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading cryogenic logistics company committed to providing innovative, reliable and efficient logistics solutions to the life sciences industry, today announced financial results for the three and six-month periods ended September 30, 2016.
Nov 07, 2016 08:30 am ET
Cryoport to Report Second Quarter Fiscal 2017 Financial Results on November 14th
IRVINE, Calif., Nov. 7, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company committed to providing innovative, reliable and efficient logistics solutions to the life sciences industry, today announced that the Company will report financial results for the second quarter of fiscal year 2017 ended September 30, 2016 on November 14, 2016 after U.S. markets close.  Cryoport's senior management will discuss financial results for the quarter ended September 30, 2016, review recent corporate developments and provide a general busine
Nov 03, 2016 09:30 am ET
Cryoport Completes Warrant Tender Offer
IRVINE, Calif., Nov. 3, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company") the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced it has received gross proceeds of approximately $3.7 million from warrants tendered and exercised in connection with its previously announced warrant exchange offer (the "Offer") that expired on Friday, October 28, 2016.
Nov 03, 2016 08:40 am ET
Lattice Biologics Inks Strategic Partnerships With OA Centers of America, Resilience, and Cryoport
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics"), an emerging biotech leader in cellular therapies and tissue engineering, with an emphasis on bone, skin, and cartilage regeneration, is pleased to announce two new...
Oct 25, 2016 09:30 am ET
Cryoport Supporting Over 100 Clinical Trials
IRVINE, Calif., Oct. 25, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or "the Company"), the world's leading cryogenic logistics company dedicated to the life sciences, today announced that it is now supporting over 100 clinical trials, 16 of which are currently in Phase 3, generally, the last phase to be approved by the FDA before commercialization.
Oct 04, 2016 09:00 am ET
Cryoport Wins 2016 Cold Chain Global Forum Excellence Award
IRVINE, Calif., Oct. 4, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences, announced today that the Company has won the 2016 Cold Chain Global Forum Excellence Award. The Awards program is the largest and most recognized annual industry event, honoring and celebrating the innovators and thought leading professionals and organizations which have substantially exceeded industry standards. The awards are to highlight the very best of these projects, and give international, industry-wide reco
Sep 30, 2016 09:00 am ET
"The Science Behind Logistics" Webinar, Hosted by Cryoport
IRVINE, Calif., Sept. 30, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company, announced today that Dr. Mark Sawicki, Chief Commercial Officer, is scheduled to present a webinar titled "The Science Behind Logistics" discussing how new therapeutic products require new technologies, capabilities, resources and a thorough understanding of how temperature impacts preclinical and clinical studies and commercialization of regenerative medicines, as follows:
Sep 29, 2016 10:38 am ET
Cryoport to Present at 2016 Cell & Gene Meeting on the Mesa
IRVINE, Calif., Sept. 29, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences, announced today that Dr. Mark Sawicki, Chief Commercial Officer, will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa, to be held October 5-7 in La Jolla, California.
Sep 22, 2016 05:14 pm ET
Cryoport and Database Integrations Launch Integrated Solution to Manage Patient and Manufacturer Schedules at Every Stage of the Clinical Trial Logistics Process
IRVINE, Calif., Sept. 22, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences, today announced the integration of its proprietary logistics technology, the Cryoportal™, with Database Integrations, Inc.'s Integrated Cell Therapy Automated Network (iCAN) scheduling platform. The integration of these two platforms is designed to solve the challenges of manufacturing, distribution and global supply chain planning for the clinical development and commercialization of cell and gene therapy products.
Sep 12, 2016 09:00 am ET
Cryoport Provides Critical Assessment of the Impact of Packaging and Logistics Decisions on the CAR-T Clinical Pipeline
IRVINE, Calif., Sept. 12, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company, announced today that Dr. Mark Sawicki, Chief Commercial Officer, is scheduled to present at the 2nd Annual CAR &TCR Summit 2016 in Boston, as follows:
Aug 29, 2016 09:00 am ET
Cryoport Partners with KCAS Bioanalytical and Biomarker Services and Heat Biologics on Comprehensive Logistics Study for Bioanalytical and Clinical Trial Materials
IRVINE, Calif., Aug. 29, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading temperature-controlled logistics company serving the life sciences industry, today announced that it has initiated a novel and comprehensive logistics study to evaluate the impact of temperature and transport packaging at deep frozen temperatures on critical biomarkers and cell-therapy cancer vaccines, respectively, in conjunction with partners KCAS Bioanalytical and Biomarker Services ("KCAS") and Heat Biologics, Inc. ("Heat"). 
Aug 15, 2016 05:10 pm ET
Cryoport Continues to Climb, Reporting 34% Revenue Growth for the First Quarter of Fiscal Year 2017
IRVINE, Calif., Aug. 15, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CRYXW), the world's leading cryogenic logistics company serving the life sciences industry, today announced financial results for the three-month period ended June 30, 2016.
Aug 11, 2016 09:00 am ET
Cryoport Expands Agreement with Stemedica to Support a Phase II Clinical Trial to Assess a Stem Cell Therapy for the Treatment of Alzheimer's Disease
IRVINE, Calif., Aug. 11, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company, today announced it has expanded its contract with Stemedica Cell Technologies, Inc. ("Stemedica") to provide cold chain logistics support for a Phase II clinical trial to assess the safety, tolerability and preliminary efficacy of allogeneic stem cell-based therapies in the treatment of Alzheimer's disease.  
Aug 02, 2016 09:00 am ET
Cryoport to Support World-Leading Life Science Company's Custom Development and Biologics Manufacturing Business
IRVINE, Calif., Aug. 2, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company, today announced that one of the world's foremost contract manufacturers to the biopharma industry ("the Client") will convert its fleet of liquid nitrogen dewars supporting shipping of its contract manufacturing biologics and cell therapy businesses to Cryoport's industry-leading and comprehensive logistics solutions. Cryoport solutions include comprehensive order entry information, customs management, innovative real time tracking, intervention wher
Aug 01, 2016 12:35 pm ET
Cryoport to Report First Quarter Fiscal 2017 Financial Results on August 15th
IRVINE, Calif., Aug. 1, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company, today announced that the Company will release financial results for the first quarter fiscal year 2017 ended June 30, 2016 on August 15, 2016 after U.S. markets close.  Cryoport will provide an update on revenue from its three main lines of business – Biopharma, Animal Health and Reproductive Medicine.  Management will also report on new client activities and provide a general business outlook.
Jun 27, 2016 05:05 pm ET
Cryoport Reports 50% Revenue Growth for Fiscal Year 2016
IRVINE, Calif., June 27, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company") today announced financial results for the three and twelve-month periods ended March 31, 2016.
Jun 21, 2016 10:23 am ET
Cryoport Successfully Completes Its Rights Offering
IRVINE, Calif., June 21, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (the "Company"), the world's leading cryogenic logistics company, announced that it has received gross proceeds of $1,304,748 in subscriptions for 841,773 shares of common stock from its previously announced rights offering, which expired on Monday, June 20, 2016 at 5:00 p.m. ET.
Jun 20, 2016 09:30 am ET
Cryoport Launches Next Generation Condition Monitoring Technology
IRVINE, Calif., June 20, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company, announced today the launch of its new SmartPak II™ Condition Monitoring System.  It is configured to provide end-to-end visibility on the real-time condition and location of critical biological commodities. The SmartPak IITM measures a variety of environmental variables and works in conjunction with the Company's Cryoportal™ logistics management platform to provide comprehensive and seamless monitoring of commodity conditions and Cryoport Express™ shipper
Jun 16, 2016 09:30 am ET
Cryoport to Report Fourth Quarter and Fiscal 2016 Financial Results on June 27th
IRVINE, Calif., June 16, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), today announced that the Company will release financial results for the fourth quarter and fiscal year 2016 ended March 31, 2016 on June 27, 2016 after the market closes.
Jun 15, 2016 10:15 am ET
Cryoport Enters Bio-Storage Market
IRVINE, Calif., June 15, 2016 /PRNewswire/ -- Cryoport, Inc. (CYRX) ("Company"), the world's leading cryogenic logistics company, today announced the launch of its bio-storage offering. The new offering is the result of a clear demand from Cryoport customers to complement its leading cryogenic logistics solutions with advanced storage and fulfillment capabilities. Cryoport Biostorage will support cryogenic storage, fulfillment, and transportation of all valuable and often irreplaceable temperature-sensitive biologic material, including clinical trial samples, vaccines, stem cells, regenerati
Jun 10, 2016 10:21 am ET
Cryoport Reminds Record Date Rights Holders for the Rights Offering to Submit all Subscriptions to Their Broker or Subscription Agent
IRVINE, Calif., June 10, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (the "Company"), the world's leading cryogenic logistics company, would like to remind its rights offering shareholders and warrant holders of record that they have the right, but not the obligation, to exercise their non-transferable basic subscription rights for $1.55 per common share, which allows its shareholders and warrant holders of record to acquire additional shares of common stock (the "rights offering").
Jun 08, 2016 09:00 am ET
Cryoport Signs Strategic Agreement to Support Tissue Solutions Transportation of Human Cells and Cryopreserved Cell Lines
IRVINE, Calif., June 8, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company") announced today that its industry leading cryogenic logistics solutions, including cryogenic shipping, logistics support and chain of condition monitoring,  are supporting Tissue Solutions  ("Tissue Solutions") as it transports products from their global network of more than 100 locations. Tissue Solutions is a leading supplier of human bio specimens to the pharmaceutical and biotech industries worldwide, specializing in the supply of high quality, ethically sourced human tissue and bio fluids for c
May 25, 2016 10:15 am ET
Cryoport Reminds All Interested Parties That Today is the Final Day to Become a Rights Offering Record Date Holder
IRVINE, Calif., May 25, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (the "Company"), the world's leading cryogenic logistics company,would like to remind the investment community that an investor must own CYRX, CYRXW or any other Cryoport warrants by 4:00 PM ET on Wednesday, May 25, 2016 in order to be considered a record date holder for purposes of the Rights Offering.
May 23, 2016 09:00 am ET
Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation's Phase I Clinical Trial for the Treatment of Parkinson's Disease
IRVINE, Calif., May 23, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company for the life sciences industry, today announced that it will provide global logistics support to International Stem Cell Corporation's (OTCQB: ISCO) ("ISCO") for its Phase I clinical trial in Australia for the treatment of moderate to severe Parkinson's disease. ISCO commenced patient enrollment for the study earlier this month.
May 16, 2016 09:49 am ET
Cryoport Announces Share Pricing Period and Record Date for Shareholder and Warrant Holder Rights Offering
IRVINE, Calif., May 16, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company, announced today the pricing period and record date for its rights offering.
May 06, 2016 10:15 am ET
Cryoport Agreement with Cryo Store BV Expands European Presence for its Best-in-Class Cryogenic Logistics Solutions
IRVINE, Calif., May 6, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company, today announced that Cryo Store BV ("Cryo Store"), a European biostorage company, will utilize Cryoport's cryogenic logistics solutions to better serve the logistics needs of life sciences customers. Cryo Store provides storage and distribution services for temperature-controlled goods to biotechnology and pharmaceutical companies in Europe.
Apr 28, 2016 07:00 pm ET
Cryoport Files S-1 Registration Statement for Rights Offering
IRVINE, Calif., April 28, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CRYXW) ("Company"), the world's leading cryogenic logistics company, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") for a rights offering to its shareholders and warrant holders of record.   
Apr 13, 2016 09:00 am ET
Cryoport Signs Strategic Partnership Deal With Worthington Industries
IRVINE, Calif., April 13, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), the world's leading cryogenic logistics company, announced today that it has entered into a strategic partnership with Worthington Industries (NYSE: WOR), maker of cryogenic storage vessels and equipment. Through this partnership, Worthington's CryoScience by Taylor Wharton business will design and manufacture biostorage and logistics equipment for use in Cryoport's life sciences cryogenic logistics solutions.
Apr 11, 2016 09:00 am ET
Cryoport Announces Global Temperature Controlled Logistics Consulting Services
IRVINE, Calif., April 11, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company, announced the launch of a new Temperature Controlled Logistics Consulting Division to assist life sciences companies in developing strategies for global cold chain logistics management and contingency options to protect their valuable, and often irreplaceable, biological commodities.
Apr 04, 2016 10:19 am ET
Cryoport Chosen to Provide Cold Chain Logistics Support to ProteoGenex
IRVINE, Calif., April 4, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company, today announced it is providing cryogenic logistics solutions that support ProteoGenex, Inc.'s ("ProteoGenex") shipping of biological specimens, including PBMCs, BMMCs, frozen tissue, OCT-embedded tissue, blood serum, blood plasma, whole blood, RNA/DNA, and other bio-fluids.
Mar 15, 2016 09:00 am ET
UPS Adds Cryogenic Shipping to Its Temperature-Sensitive Portfolio In Europe
BRUSSELS, March 15, 2016 /PRNewswire/ -- UPS (NYSE: UPS) announced the launch of UPS Temperature True® Cryo in Europe, providing healthcare customers access to end-to-end product protection and capability to ship parcels in a cryogenic environment. The service includes real-time tracking and intervention, which, when combined with UPS's risk mitigation solutions and global network of control towers, will provide complete visibility for shipments at every stage of the supply chain journey.
Mar 03, 2016 08:00 am ET
Cryoport Supports ImmunoCellular Therapeutics' 120-Site Phase III Clinical Trial With Cold Chain Logistics
IRVINE, Calif., March 3, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company, today announced that it will be supporting the cryogenic logistics requirements of ImmunoCellular Therapeutics' (NYSE MKT: IMUC) ("ImmunoCellular") registrational Phase III glioblastoma clinical trial across 120 sites in North America and Europe. This clinical trial is designed to evaluate the safety and efficacy of ImmunoCellular's lead product candidate ICT-107, a patient-derived dendritic cell-based immunotherapy.  
Feb 16, 2016 08:00 am ET
Cryoport Supports Perseus PCI in Melanoma and Ovarian Cancer Clinical Trials
IRVINE, Calif., Feb. 16, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (the "Company"), the world's leading cryogenic logistics company, announced today that it will manage the cryogenic shipping of solid tumor samples and vaccine for Perseus PCI's ("Perseus") melanoma and ovarian cancer clinical trials.
Feb 08, 2016 09:00 am ET
Cryoport Reports 50% Revenue Growth for the Third Quarter of Fiscal Year 2016
IRVINE, Calif., Feb. 8, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company") today announced financial results for the three and nine-month periods ended December 31, 2015.
Feb 04, 2016 08:30 am ET
Cryoport to Present at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
IRVINE, Calif., Feb. 4, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), the world's leading cryogenic logistics company, today announced that Jerrell Shelton, Chief Executive Officer of Cryoport, Inc, will present at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference to be held at the Convene, 730 Third Avenue in New York City on Wednesday, February 10, 2016 at 10:15am ET.
Feb 02, 2016 08:00 am ET
Cryoport to Report Third Quarter Fiscal 2016 Financial Results on February 8th
IRVINE, Calif., Feb. 2, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), today announced that the Company will release financial results for the third quarter fiscal year 2016 ended December 31, 2015 on February 8, 2016 before the market opens.
Jan 26, 2016 08:30 am ET
Cryoport Introduces Its Advanced Cryogenic Logistics Solutions for IVF to the Cambodia and Czech Republic Markets
IRVINE, Calif., Jan. 26, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the leading global cryogenic logistics company for the life sciences industry, today announced the geographic expansion of its Reproductive Medicine (IVF) shipping and logistics solutions to include Cambodia and the Czech Republic.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.